A prospective survey of atrial fibrillation management in Iran: Baseline results of the Iranian Registry of Atrial Fibrillation (IRAF)

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia globally and increases the risk of mortality and morbidity from stroke, systemic embolism, heart failure (HF), and dementia. [1][2][3] Several studies have demonstrated that AF is mainly associated with advancing age and underlying cardiovascular disease, particularly hypertension and coronary artery disease. Our current understanding of AF is largely based on data from North America and Europe. 4-7 Regional cohort studies have suggested that rheumatic heart disease, diabetes, obesity, and smoking are more important causes of AF than in other regions in the world. 8,9 There are racial and ethnic differences in AF symptom, treatment patterns, and outcomes. 9,10 During the previous four decades, several effective therapies for AF have been developed, 11,12 particularly, the use of direct-acting

Whole-exome sequencing reveals a rare missense variant in DTNA in an Iranian pedigree with early-onset atrial fibrillation

“…In familial cases, nearly 1 in 4 patients has a first-degree relative who suffers from AF [ 12 ]. According to the Iranian Registry of Atrial Fibrillation, history of AF in a first-degree relative is positive in 15.3% of the Iranian AF population [ 7 , 13 ].…”